Salvage radiotherapy improves survival in patients with locoregionally relapsed stage IE–IIE extranodal natural killer/T-cell lymphoma, nasal type
Authors Tong Q, Ouyang SM, Feng LL, Wang HY, Xia YF, Zhang YJ
Received 2 February 2018
Accepted for publication 12 April 2018
Published 6 June 2018 Volume 2018:14 Pages 1083—1090
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Qin Tong,1,* Shuming Ouyang,2,* Lingling Feng,3,* Hanyu Wang,3 Yunfei Xia,3 Yujing Zhang3
1Department of Radiation Oncology, The First Affiliated Hospital of University of South China, Hengyang 421001, People’s Republic of China; 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of South China, Hengyang 421001, People’s Republic of China; 3Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, People’s Republic of China
*These authors contributed equally to this work
Background: This study aims to retrospectively analyze the salvage treatment outcomes and prognostic factors of patients with early stage locoregionally recurrent (LRR) extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL).
Methods: Between January 1995 and December 2014, 540 patients with stage IE–IIE ENKTCL received chemotherapy (ChT) and/or radiotherapy (RT) in our hospital, and among these, 56 patients who experienced LRR were included in this study. Salvage treatments included RT alone in 4 patients (7.1%), ChT alone in 30 patients (53.6%), and ChT combined with RT in 22 patients (39.3%). Median RT dose was 50 Gy (range 36–60 Gy). The effect of salvage treatment on overall survival (OS) rate from start of initial treatment (IT) as well as that after recurrence was analyzed.
Results: The overall median follow-up time from IT was 35.9 months, with a 3-year OS of 72.7%. The median follow-up time after relapse was 14.8 months, and the 3-year OS after relapse was 57.8%. Compared to ChT alone (n=30), treatment with salvage RT (n=26) improved the OS from IT (p=0.040) and after relapse (p=0.009); further, re-irradiation improved the OS from IT (p=0.018) and after relapse (p=0.019). Acute and late toxicities after re-irradiation were mostly grades 1–2 (84.3%). At both univariate and multivariate analyses, better Karnofsky Performance Score (KPS), RT in IT, and RT in salvage treatment were found to be significant factors influencing OS after recurrence.
Conclusion: Salvage RT improved survival in patients with LRR stage IE–IIE ENKTCL, and the treatment toxicity was acceptable.
Keywords: extranodal NK/T-cell lymphoma, nasal type, radiotherapy, recurrence, prognostic analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]